Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California. more
Time Frame | RENB | Sector | S&P500 |
---|---|---|---|
1-Week Return | -14.43% | 0.49% | -0.42% |
1-Month Return | -51.68% | -3.1% | -2.2% |
3-Month Return | 79.93% | -8.59% | 2.38% |
6-Month Return | -47.87% | -4.57% | 5.1% |
1-Year Return | -81.99% | -0.94% | 23.79% |
3-Year Return | -87.38% | 2.88% | 26.66% |
5-Year Return | -82.85% | 35.84% | 81.16% |
10-Year Return | -86.79% | 98.8% | 191.72% |
Jun '20 | Jun '21 | Jun '22 | Jun '23 | Jun '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}] |
Cost of Revenue | 366.27K | 391.42K | 123.59K | 113.50K | 121.86K | [{"date":"2020-06-30","value":93.58,"profit":true},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":31.58,"profit":true},{"date":"2023-06-30","value":29,"profit":true},{"date":"2024-06-30","value":31.13,"profit":true}] |
Gross Profit | (366.27K) | (391.42K) | (123.59K) | (113.50K) | (121.86K) | [{"date":"2020-06-30","value":-36626900,"profit":false},{"date":"2021-06-30","value":-39141600,"profit":false},{"date":"2022-06-30","value":-12359000,"profit":false},{"date":"2023-06-30","value":-11349600,"profit":false},{"date":"2024-06-30","value":-12185900,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | - | [{"date":"2020-06-30","value":null,"profit":false},{"date":"2021-06-30","value":null,"profit":false},{"date":"2022-06-30","value":null,"profit":false},{"date":"2023-06-30","value":null,"profit":false},{"date":"2024-06-30","value":"-","profit":true}] |
Operating Expenses | 11.92M | 23.40M | 22.83M | 19.60M | 81.64M | [{"date":"2020-06-30","value":14.61,"profit":true},{"date":"2021-06-30","value":28.66,"profit":true},{"date":"2022-06-30","value":27.96,"profit":true},{"date":"2023-06-30","value":24,"profit":true},{"date":"2024-06-30","value":100,"profit":true}] |
Operating Income | (11.92M) | (23.40M) | (116.08M) | (38.56M) | (81.64M) | [{"date":"2020-06-30","value":-1192376800,"profit":false},{"date":"2021-06-30","value":-2340178700,"profit":false},{"date":"2022-06-30","value":-11607919100,"profit":false},{"date":"2023-06-30","value":-3855689100,"profit":false},{"date":"2024-06-30","value":-8163929600,"profit":false}] |
Total Non-Operating Income/Expense | 507.41K | (3.81M) | 2.39M | (1.83M) | - | [{"date":"2020-06-30","value":21.19,"profit":true},{"date":"2021-06-30","value":-159.24,"profit":false},{"date":"2022-06-30","value":100,"profit":true},{"date":"2023-06-30","value":-76.59,"profit":false},{"date":"2024-06-30","value":"-","profit":true}] |
Pre-Tax Income | (11.42M) | (26.85M) | (113.43M) | (39.68M) | (80.65M) | [{"date":"2020-06-30","value":-1141635800,"profit":false},{"date":"2021-06-30","value":-2684888300,"profit":false},{"date":"2022-06-30","value":-11343335800,"profit":false},{"date":"2023-06-30","value":-3968405600,"profit":false},{"date":"2024-06-30","value":-8065017200,"profit":false}] |
Income Taxes | 104.28K | (125.28K) | 34.00 | 706.96K | 1.00 | [{"date":"2020-06-30","value":14.75,"profit":true},{"date":"2021-06-30","value":-17.72,"profit":false},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":"-","profit":true}] |
Income After Taxes | (11.52M) | (26.72M) | (113.43M) | (40.39M) | - | [{"date":"2020-06-30","value":-1152063800,"profit":false},{"date":"2021-06-30","value":-2672360700,"profit":false},{"date":"2022-06-30","value":-11343339200,"profit":false},{"date":"2023-06-30","value":-4039102000,"profit":false},{"date":"2024-06-30","value":"-","profit":true}] |
Income From Continuous Operations | (11.42M) | (26.72M) | (113.43M) | (39.68M) | - | [{"date":"2020-06-30","value":-1141635800,"profit":false},{"date":"2021-06-30","value":-2672360700,"profit":false},{"date":"2022-06-30","value":-11343339200,"profit":false},{"date":"2023-06-30","value":-3968405600,"profit":false},{"date":"2024-06-30","value":"-","profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}] |
Net Income | (11.42M) | (26.72M) | (113.43M) | (39.68M) | (80.65M) | [{"date":"2020-06-30","value":-1141635800,"profit":false},{"date":"2021-06-30","value":-2672360700,"profit":false},{"date":"2022-06-30","value":-11343339200,"profit":false},{"date":"2023-06-30","value":-3968405600,"profit":false},{"date":"2024-06-30","value":-8065017100,"profit":false}] |
EPS (Diluted) | (0.25) | (0.56) | (2.15) | (2.28) | (0.47) | [{"date":"2020-06-30","value":-25,"profit":false},{"date":"2021-06-30","value":-56,"profit":false},{"date":"2022-06-30","value":-215.24,"profit":false},{"date":"2023-06-30","value":-228.39,"profit":false},{"date":"2024-06-30","value":-47.1,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
RENB | |
---|---|
Cash Ratio | 0.01 |
Current Ratio | 0.08 |
Quick Ratio | 0.10 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RENB | |
---|---|
ROA (LTM) | -15.46% |
ROE (LTM) | -90.38% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RENB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.19 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.81 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RENB | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 1.35 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Renovaro Biosciences Inc (RENB) share price today is $0.7924
Yes, Indians can buy shares of Renovaro Biosciences Inc (RENB) on Vested. To buy Renovaro Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RENB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Renovaro Biosciences Inc (RENB) via the Vested app. You can start investing in Renovaro Biosciences Inc (RENB) with a minimum investment of $1.
You can invest in shares of Renovaro Biosciences Inc (RENB) via Vested in three simple steps:
The 52-week high price of Renovaro Biosciences Inc (RENB) is $5.25. The 52-week low price of Renovaro Biosciences Inc (RENB) is $0.4.
The price-to-earnings (P/E) ratio of Renovaro Biosciences Inc (RENB) is
The price-to-book (P/B) ratio of Renovaro Biosciences Inc (RENB) is 1.35
The dividend yield of Renovaro Biosciences Inc (RENB) is 0.00%
The market capitalization of Renovaro Biosciences Inc (RENB) is $125.77M
The stock symbol (or ticker) of Renovaro Biosciences Inc is RENB